Go to the list of all blogs
AI dvisor's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Veeva Systems (VEEV) Analysts Target $345, Implying +31% Upside

Veeva Systems (VEEV) Analysts Target $345, Implying +31% Upside

Key Takeaways

  • The central $345 stock price target is the arithmetic mean of 12 verified, current analyst price targets published in November 2026, and it sits roughly 31% above the latest market price.
  • Veeva Systems Inc. (VEEV) last traded near $262.92, so the target requires a substantial advance of about 31% from current levels.
  • The verified analyst range is wide — from $275 (Morgan Stanley) to $400 (Wells Fargo) — reflecting genuine disagreement about valuation and growth durability rather than a uniform bullish view.
  • Supporting factors include mid-teens revenue growth, raised fiscal 2027 EPS guidance, and continued Vault CRM adoption by large pharmaceutical clients.
  • The biggest risks are a premium valuation, insider selling, maturing core product lines, and intensifying competition.
  • Next earnings, scheduled around December 3, 2026, is a key catalyst for the path toward the target.
  • For additional context, explore Major News, Today's Price Move, the Forecast, and Earnings pages to follow the latest developments.
  • You can also explore Trending AI Robots to see how automated strategies are tracking opportunities across the market.

Analyst Price Targets: A Closer Look at the Consensus

Veeva Systems Inc. (VEEV) is a provider of cloud-based software for the life sciences industry, not an exchange-traded fund. The $345 central target was calculated as the arithmetic mean of 12 current analyst price targets identified by firm, analyst, and date, published between November 6 and November 19, 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Those targets run from $275 (Morgan Stanley, Hold) to $400 (Wells Fargo, Buy), with a cluster of bullish estimates between $360 and $375 from firms including BTIG, Truist, Jefferies, Barclays, and Needham. Neutral-to-cautious views sit lower, with BMO Capital at $300, UBS at $310, and Canaccord Genuity at $315. The mean of the 12 targets is approximately $344.58, rounded to $345. Broader aggregator tallies that include additional bearish estimates show a wider low near $180, which underscores how divided the Street remains.

The overall rating skew is bullish — most firms rate the stock Buy or Overweight — but the wide dispersion means this is not a tightly clustered consensus. Bullish analysts emphasize durable subscription revenue, market-share gains in life sciences CRM, and new AI-related products, while cautious analysts argue that core products are maturing and that much of the optimism is already reflected in the valuation.

Where VEEV Stands Today and the Path to the Target

VEEV closed near $262.92 on November 19, 2026, a sharp single-session decline from the prior close of $277.20. Reaching $345 would require a gain of roughly 31%, a substantial move by most standards. The shares have traded in a wide 52-week range of about $148.05 to $325.99, meaning the stock has already demonstrated the capacity for large swings in both directions.

The path toward the target rests on sustained execution: Veeva reported revenue of $927.96 million for its July-quarter, up about 17.6% year over year and above consensus estimates, and it has raised its full-year fiscal 2027 EPS guidance to $9.21, well above the roughly $8.58 consensus. The company trades at a trailing P/E near 43 and a forward P/E near 27, so continued estimate increases, rather than multiple expansion alone, would be the more durable route higher.

Factors That Could Drive the Stock Higher

Several verified factors support the bullish case. Revenue growth remains in the mid-teens, gross margins are near 75%, and Veeva continues to convert large pharmaceutical customers to Vault CRM — recent wins include UCB, Amgen, and Roche Pharma. The company has also been rolling out AI-driven products such as Falcon Safety and agentic biopharma tools, which analysts view as potential new growth vectors. Management's decision to raise full-year guidance, combined with a reported $2 billion buyback authorization, signals confidence in cash generation and profitability.

Risks That Could Hold It Back

The principal obstacle is valuation. At a trailing P/E in the low 40s, the stock leaves limited room for error, and any deceleration in revenue growth could compress the multiple. Insider selling has picked up, with several officers and directors reducing positions in recent months, and short interest remains elevated. Competition in life sciences software is intensifying, and some analysts — including a Sell-rated view from Goldman Sachs earlier in 2026 — argue that core Commercial products are maturing and that new product ramps lack visibility, creating downside risk to consensus expectations.

Technical Levels to Watch

The 52-week high near $326 is a meaningful resistance level, and $300 has served as a psychological battleground in recent sessions. On the downside, the stock's recovery from its April/June 2026 lows near $148 means a zone of support exists in the $250 area, with further support around $200. A sustained move toward $345 would first require the stock to reclaim and hold above $300, then break through the prior high near $326.

What to Monitor Going Forward

Analyst price targets generally reflect a research horizon of about 12 months, though the horizon is not always stated explicitly and varies by firm. Investors tracking whether VEEV can move toward $345 should monitor the December 3, 2026 earnings report and guidance update, any further analyst target revisions, the pace of Vault CRM customer migrations, developments in AI products, and broader software-sector multiple compression. Macro conditions, including interest-rate expectations, also matter for a stock with a premium valuation.

Using AI Tools to Track VEEV

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors watching VEEV, these signals offer a data-driven complement to fundamental research. I find this helpful when I want to see how the broader market is interpreting the same data points I review manually.

Final Assessment

The $345 central target is an analyst-derived average — the mean of 12 current, verified price targets — and it implies a substantial move of roughly 31% from the recent price near $262.92. Support comes from solid revenue growth, raised guidance, and large-customer CRM migrations, while the principal obstacles are a premium valuation, insider selling, and disagreement about whether growth can be sustained as core products mature. The unusually wide analyst range, from $275 to $400, indicates that even professionals hold sharply divergent views. Reaching $345 is plausible only if execution stays strong and estimates keep rising, but it is not a guaranteed outcome and should not be treated as one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VEEV

Momentum Indicator for VEEV turns negative, indicating new downward trend

VEEV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 54 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 69%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.

VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 133 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was 5%. DH experienced the highest price growth at 5%, while DRIO experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 54
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: 0 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of industry-specific, cloud-based software solutions for the life sciences industry

Industry ServicestotheHealthIndustry

Industry
Packaged Software
Address
4280 Hacienda Drive
Phone
+1 925 452-6500
Employees
7928
Web
https://www.veeva.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.